**Table S1 - Some other clinical characteristics of patients with sepsis.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Other clinical characteristics** | **Pre-protocol,**  **n = 84** | | **Post-protocol, n = 103** | | **Total,**  **n = 187** | |
| **Admitting specialty** |  |  |  |  |  |  |
| General surgery | 14 | (17) | 18 | (18) | 32 | (17) |
| Hematology | 1 | (1) | 8 | (8) | 9 | (5) |
| Hepatology | 29 | (35) | 36 | (35) | 65 | (35) |
| Nephrology | 5 | (6) | 14 | (14) | 19 | (10) |
| Neurosurgery | 6 | (7) | 7 | (6) | 13 | (7) |
| Oncology | 3 | (4) | 7 | (6) | 10 | (5) |
| Orthopedics | 24 | (29) | 13 | (13) | 37 | (20) |
| Plastic surgery | 2 | (1) | 0 | (0) | 2 | (1) |
| **Initial antibiotic regimen** |  |  |  |  |  |  |
| Amikacin | 18 | (22) | 1 | (1) | 19 | (10) |
| Cefepime | 28 | (33) | 27 | (26) | 55 | (29) |
| Cefepime + Clarithromycin | 1 | (1) | 0 | (0) | 1 | (1) |
| Cefepime + Teicoplanin | 1 | (1) | 0 | (0) | 1 | (1) |
| Cefepime + Vancomycin | 7 | (8) | 18 | (17) | 25 | (13) |
| Ciprofloxacin | 0 | (0) | 2 | (2) | 2 | (1) |
| Linezolid | 0 | (0) | 1 | (1) | 1 | (1) |
| Meropenem | 18 | (22) | 32 | (31) | 50 | (26) |
| Meropenem + Vancomycin | 11 | (13) | 9 | (9) | 20 | (11) |
| Piperacillin + Tazobactam | 0 | (0) | 6 | (6) | 6 | (3) |
| Others | 0 | (0) | 7 | (7) | 7 | (4) |
| **Type of colonization** |  |  |  |  |  |  |
| ESBL | 28 | (34) | 38 | (37) | 66 | (35) |
| MRSA | 2 | (2) | 3 | (3) | 5 | (3) |
| Non-colonized | 54 | (64) | 62 | (60) | 116 | (62) |

ESBL, Extended-spectrum beta-lactamase; MRSA, Methicillin-resistant Staphylococcus aureus.

a The total does not add up to 100% due to the occurrence of symptom overlap.